Abiopharma

🔍 Currault Douglas N. II (Executive)

Company: FREEPORT-MCMORAN INC (FCX)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Acquired 65,000 shares of Common Stock at $12.04 per share (Direct)
  Date: 2026-08-25 | Code: M | equity_swap_involved: false | shares_owned_after: 276,016.00 | transaction_form_type: 4
• Acquired 15,000 shares of Common Stock at $28.14 per share (Direct)
  Date: 2026-08-25 | Code: M | equity_swap_involved: false | shares_owned_after: 291,016.00 | transaction_form_type: 4
• Sold 80,000 shares of Common Stock at $78.5558 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: false | shares_owned_after: 211,016.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 65,000 shares of Options (Right to Buy) at $12.04 per share (Derivative)
  Date: 2026-08-25 | Code: M | Expires: 2030-02-04 | Exercise: 2021-02-04 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2
• Sold 15,000 shares of Options (Right to Buy) at $28.14 per share (Derivative)
  Date: 2026-08-25 | Code: M | Expires: 2031-02-02 | Exercise: 2022-02-02 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The price reported represents the weighted average price of the shares sold. Shares were sold at varying prices in the range of $78.5500 - $78.5950. The Reporting Person here undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
• F2: Options granted were 33% exercisable on the date indicated and 33% exercisable on each of the next two anniversaries thereof.
• F3: Options granted were 33% exercisable on the date indicated and 33% exercisable on each of the next two anniversaries thereof.
• F4: Amount beneficially owned includes 36,499 Common Stock Restricted Stock Units.